Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01646593|
Expanded Access Status : No longer available
First Posted : July 20, 2012
Last Update Posted : December 15, 2014
|First Submitted Date||July 18, 2012|
|First Posted Date||July 20, 2012|
|Last Update Posted Date||December 15, 2014|
|Brief Title||Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy|
The objective of the trial is to provide regorafenib to subjects diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.
Selected additional safety information on regorafenib will be collected and progression-free survival (PFS) will be estimated.
|Detailed Description||Not Provided|
|Study Type||Expanded Access|
|Intervention||Drug: Regorafenib (BAY73-4506)
160 mg BAY73-4506, 3 weeks on drug, 1 week off
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Expanded Access Status||No longer available|
|Contacts||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries||Not Provided|
|Removed Location Countries||United States|
|Responsible Party||Therapeutic Area Head, Bayer Healthcare AG|
|Verification Date||December 2014|